Peptides Marketed for Muscle Growth Aren’t a Regulatory Loophole. Most Are on WADA’s Banned List.
Here’s the real list of peptides sold for muscle growth, organized by how they’re actually theorized to work, plus a fact most guides on this topic skip entirely: nearly every GH-axis compound on this list is a prohibited substance in organized sport, at all times, not just on competition day.
Reviewed by the PepGuard team · Last reviewed Jul 28, 2026
- GH-axis secretagogues (CJC-1295, ipamorelin, GHRP-2, hexarelin, sermorelin, tesamorelin) raise the body's own growth hormone; IGF-1 LR3 and PEG-MGF act more directly on growth-factor pathways.
- Tesamorelin is the only FDA-approved compound in this group, and its approval is for HIV-associated lipodystrophy, not muscle growth.
- Most GH-axis peptides are explicitly named in WADA's Prohibited List, category S2, banned both in and out of competition.
- BPC-157 is the one exception, it doesn't appear anywhere in WADA's current Prohibited List, unlike its usual stacking partner TB-500.
Photo: Alora Griffiths / UnsplashHow these peptides are theorized to build muscle.
Two distinct mechanisms get marketed under the same “muscle growth” heading. The first, and by far the more common, is indirect: a peptide prompts the pituitary gland to release more of the body’s own growth hormone, which in turn raises circulating IGF-1, a hormone with a well-established role in muscle protein synthesis. None of these peptides directly build muscle tissue themselves, they’re upstream signals.
The second mechanism is more direct: growth-factor peptides like IGF-1 LR3 are marketed as mimics of the downstream signal itself, rather than a prompt for the body to produce more of it. Separately, tissue-repair peptides like BPC-157 and TB-500 get stacked alongside either approach, not for growth itself but for recovery between training sessions, a different mechanism entirely.
The GH-axis secretagogues.
| Peptide | Mechanism | FDA status | WADA status |
|---|---|---|---|
| CJC-1295 + Ipamorelin | GHRH analog + ghrelin-receptor agonist | Not approved | Prohibited, S2.2.4 |
| GHRP-2 | GH-releasing peptide | Approved in Japan, diagnostic use only | Prohibited, S2.2.4 |
| Hexarelin | GH-releasing peptide | Not approved | Prohibited, S2.2.4 |
| Sermorelin | GHRH analog | Not currently marketed as an approved product | Prohibited, S2.2.4 |
| Tesamorelin | GHRH analog | Approved (Egrifta), HIV-associated lipodystrophy only | Prohibited, S2.2.4 |
| AOD-9604 | GH fragment | Not approved | Prohibited, S2.2.3 |
Every one of these has its own dosage and trial-evidence report on this site, click through for the actual human data behind each, not just the muscle-growth marketing claim.
The growth-factor peptides.
IGF-1 LR3 and PEG-MGF are marketed as more direct growth-factor mimetics rather than GH-release prompts. Both were originally engineered as laboratory or cell-culture reagents, not as injectable products, a distinction each page covers in full. Both are also explicitly listed in WADA’s Prohibited List, IGF-1 and its analogues under S2.3, and mechano growth factors by name in the same section.
The recovery peptides stacked alongside them.
BPC-157 and TB-500 get stacked with GH-axis peptides for a different purpose, recovery between training sessions, not growth itself, and they work through a separate tissue-repair mechanism entirely. Their anti-doping status also diverges: TB-500 is explicitly named in WADA’s Prohibited List as a Thymosin-ß4 derivative. BPC-157 is not, it does not appear anywhere in the current 2026 Prohibited List, despite being just as unapproved and just as unstudied in humans as its usual stacking partner.
The anti-doping angle most guides skip.
WADA’s 2026 Prohibited List places “growth hormone-releasing hormone (GHRH) and its analogues,” “growth hormone secretagogues (GHS) and their mimetics,” and “GH-releasing peptides (GHRPs)” all in category S2, and S2 is prohibited at all times, both in competition and out of competition. That’s a meaningfully different standard than many other prohibited categories: it doesn’t matter whether a test happens on competition day or during an off-season training block. For any athlete subject to WADA testing, this isn’t a theoretical risk attached to a gray-market supplement, it’s a named substance on an enforcement list.
Every claim above, traced back.
WADA’s own 2026 Prohibited List document and the FDA’s Egrifta approval record. Click through and check them yourself.
Muscle-growth peptide questions, answered.
Two different mechanisms get sold under this goal. GH-axis secretagogues (CJC-1295, ipamorelin, GHRP-2, hexarelin, sermorelin, tesamorelin) work by prompting the body to release more of its own growth hormone, on the theory that this raises IGF-1 and supports muscle protein synthesis. IGF-1 LR3 and PEG-MGF are marketed as more direct growth-factor mimetics. BPC-157 and TB-500 are sold alongside these for recovery, not growth itself, on a separate tissue-repair mechanism.
No. Tesamorelin (Egrifta) is the one FDA-approved compound in this group, and its approval is specifically for HIV-associated lipodystrophy, a fat-redistribution condition, not muscle growth or athletic performance. No peptide on this list has an FDA-approved bodybuilding or muscle-growth indication.
Most of them, yes, and not just on competition day. WADA's 2026 Prohibited List places growth hormone-releasing hormone analogues, growth hormone secretagogues, and GH-releasing peptides in category S2, prohibited both in and out of competition, at all times. CJC-1295, ipamorelin, GHRP-2, hexarelin, sermorelin, and tesamorelin are all explicitly named. IGF-1 and its analogues and mechano growth factors are separately listed under S2.3. TB-500 is listed too, as a Thymosin-ß4 derivative. BPC-157 is the one exception on this list, it does not currently appear anywhere in WADA's Prohibited List.
The evidence varies enormously by compound, and none of it was generated in bodybuilders training for hypertrophy. Each compound's own evidence report covers what was actually studied, in what population, and at what dose, rather than the muscle-growth claim made by vendors.
Keep researching.
A marketing claim isn't the same thing as a trial result.
Create your account to check any peptide's actual evidence and anti-doping status before it goes anywhere near your body.